Generation of Human Lak Cells in Tissue Culture Bags Using Recombinant Il-2 and Serum Free Medium Effects of pretreatment with phenylalanine-methylester

References

• Grimm E A, Mazumder A, Zhang H Z, Rosenberg S A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistent fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Lymphokine activated killer cells: a new approach to the immunotherapy of cancer. J Natl Cancer Inst 1985; 75: 595–603
   PubMed Web of Science ®Google Scholar
• Mule J J, Shu S, Schwarz S L, Rosenberg S A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant IL-2. Science 1984; 25: 1487–9
   Google Scholar
• Lafreniere R, Rosenberg S A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant IL-2. Cancer Res 1985; 45: 3753–41
   Google Scholar
• Rosenberg S A. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin 2. J Biol Response Mod 1985; 3: 501–11
   Google Scholar
• Rosenberg S A, Lotze M T, Mule L, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987; 15: 889–97
   Google Scholar
• Mesler-Muul L, Nason-Buchenal K, Carter C S, et al. Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 1987; 2: 171–81
   Google Scholar
• Yannelli J R, Thurman G B, Dickerson S G, Mrowca A, Sharp E, Oldham R K. An improved method for the generation of human lymphokine activated killer cells. J Immunol Methods 1987; 100: 137–45
   PubMed Web of Science ®Google Scholar
• Hoyer M, Meineke T, Lewis W, Zwilling B, Rinehart J. Characterization and modulation of human lymphokine (Interleukin 2) activated killer cell induction. Cancer Res 1986; 46: 2834–8
   PubMed Web of Science ®Google Scholar
• Thiele D L, Lipsky P E. Modulation of human natural killer cell function by leucine methyl ester: Monocyte-dependent depletion from human peripheral blood mononuclear cells. J Immunol 1985; 2: 786–93
   Google Scholar
• Shiiba K, Suzuki R, Kawakami K, Ohuchi A, Kumagai K. Interleukin 2-activated killer cells: generation in collaboration with interferon and its suppression in cancer patients. Cancer Immunother 1986; 21: 119–28
   Google Scholar
• Vanky F, Stejernswärd J, Klein E, Steiner L, Lindberg L. Tumor associated specificity of serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors. J Natl Cancer Inst 1973; 51: 25–32
   PubMedGoogle Scholar
• Hellström K E, Hellström I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 1974; 18: 209–77
   PubMedGoogle Scholar
• Herzberg V L, Smith K A. T cell growth without serum. J Immunol 1987; 139: 998–1004
   PubMed Web of Science ®Google Scholar
• Lindemalm C, Mellstedt H, Biberfeld P, et al. Blood and lymph node T lymphocyte subsets in non Hodgkin lymphomas. Scand J Haematol 1983; 30: 68–78
   PubMedGoogle Scholar
• Tribukait B. Flow cytometry in surgical pathology and cytology of tumors of the genito-urinary tract. Advances in clinical cytology 2, L G Koss, D Coleman. Masson, New York 1984; 163–89
   Google Scholar
• Baisch H, Göhde W, Linden W. Analysis of PCP-data to determine the fraction of cells in various phases of cell cycle. Radiat Environ Biophys 1975; 12: 31–9
   PubMed Web of Science ®Google Scholar
• Pross H F, Baines M G, Rubin P, Shtagge P, Patterson M. Spontaneous human lymphocyte mediated cytoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981; 1: 51–63
   PubMed Web of Science ®Google Scholar
• Tapuhi Y, Müller N, Kager B-L. Practical considerations in the chyrol separation of Das-amino acid by reversed phase liquid chromatography using metal chelate additives. J Chromat 1981; 205: 325–37
   Web of Science ®Google Scholar
• Bechner S K, Maluish A E, Longo D L. Lymphokine-activated killer cells: Culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors. Cancer Res 1987; 47: 5504–8
   PubMedGoogle Scholar
• Unanue E R, Allen P M. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551–7
   PubMed Web of Science ®Google Scholar
• Burton E G, Dal Monte P, Spears C, Frank P, Oppermann J A. Absorption by the rhesus monkey of phenylalanine methylester and species differences in its metabolism by blood, plasma and intestinal mucosa. J Nutr 1984; 114: 1940–5
   PubMedGoogle Scholar
• Lafreniere R, Rosenstein M S, Rosenberg S A. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. J Immunol Methods 1986; 94: 37–49
   PubMedGoogle Scholar
• Smith K A, Cantrell D A. Interleukin 2 regulates its own receptors. Proc NAtl Acad Sci 1985; 82: 864–8
   PubMed Web of Science ®Google Scholar
• Grimm E A, Ramsey K M, Mazumder A, Wilson D J, Djeu J Y, Rosenberg S A. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes. Memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983; 157: 884–97
   PubMed Web of Science ®Google Scholar
• Grimm E A, Robb R J, Roth J A, et al. Lymphokine-activated killer cell phenomenon. III. Evidence that IL2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 1983; 158: 1356–61
   PubMed Web of Science ®Google Scholar
• Rayner A A, Grimm E A, Lotze M, Chu E W, Rosenberg S A. Lymphokine-activated killer (LAK) cells. Cancer 1985; 55: 1327–33
   PubMed Web of Science ®Google Scholar
• Lanier L L, Le A M, Civin C I, Loken M R, Phillips J H. The relationship of CD 16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480–5
   PubMed Web of Science ®Google Scholar
• Damle N K, Doyle L V, Bradley E C. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 1986; 137: 2814–22
   PubMed Web of Science ®Google Scholar
• Joseph H, Phillips J H, Lewis L, Lanier L. Dissection of the lymphokine-activated killer phenomenon. J Exp Med 1986; 164: 814–25
   PubMedGoogle Scholar
• Owen-Shaub L B, Abraham S R, Hemstreet G P. Phenotypic characterization of murine lymphokine-activated killer cells. Cellular Immunol 1986; 103: 272–86
   PubMedGoogle Scholar
• Ortaldo J R, Mason A, Overton R. Lymphokine-activated killer cells. J Exp Med 1986; 164: 1193–205
   PubMed Web of Science ®Google Scholar
• Lanier L, Le M, Ding A, et al. Expression of Leu-19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines. J Immunol 1987; 138: 2019–23
   PubMed Web of Science ®Google Scholar